陈大卫：创新放射免疫治疗方案，提升肿瘤患者治愈率

Core Viewpoint - The innovation in radiotherapy and immunotherapy led by Professor Chen David and his team has significantly improved treatment efficacy for lung cancer patients, establishing new standards in clinical practice and garnering multiple prestigious awards [3][4]. Group 1: Research Achievements - The team successfully increased the treatment efficacy of lung cancer by over 100% and nearly doubled the survival period for advanced lung cancer patients [3]. - Their research has been recognized in five lung cancer treatment guidelines across the US, Europe, and China, integrating radiotherapy and immunotherapy into standard treatment protocols [3][4]. - The team has received several awards, including the 2024 National Science and Technology Progress Award (second prize) and the China Youth May Fourth Medal [3]. Group 2: Innovations in Treatment - The team has made theoretical innovations by proving the existence of the radiation abscopal effect and its mechanism mediated by the immune system [4]. - They established a combined treatment approach using large fraction radiotherapy and PD-1 inhibitors, which has been published in a top-tier medical journal and has influenced multiple treatment guidelines [4]. - A new treatment model was developed that increased efficacy from 19.7% to 41.7%, representing a 60% improvement, and has been included in various international treatment guidelines [4]. Group 3: Cost Efficiency and Accessibility - The team emphasizes the importance of standardized treatment protocols to enhance efficiency and reduce costs for cancer patients, particularly in underdeveloped areas [5]. - They advocate for multidisciplinary collaboration to create tailored treatment plans, ensuring patients receive optimal care without unnecessary expenses [5]. - Ongoing research aims to provide better treatment options that are cost-effective, ultimately benefiting patients financially [5].